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Within the context of the theory of immunological tumour surveil-
lance, the immune system is considered to play an important role
in the control and elimination of malignant cells. It is now well
established that tumour rejection can be mediated by lymphocytes,
most notably, CD8+ cytotoxic T lymphocytes (CTLs). Conse-
quently, many immunotherapy approaches have been developed to
enhance the immune response to tumours by directly activating
tumour-specific CTLs. Since immune recognition by CTLs
requires the presentation of processed peptides in association with
major histocompatibility complex (MHC) class I molecules, the
success of these cancer vaccination strategies is dependent on the
ability of the malignant cells to endogenously process and present
target epitopes on their cell surface. However, malignant transfor-
mation is frequently associated with escape of tumour cells from
immune recognition. Defects in the endogenous processing func-
tion may result in a down-regulated presentation of specific anti-
gens in the context of surface MHC class I molecules on tumour
cells (Marincola et al, 1994a; Ferrone and Marincola, 1995;
Hicklin et al, 1999) and, thus, in resistance to CTL-mediated
immune recognition (Darrow et al, 1989; Restifo et al, 1993;
Rivoltini et al, 1995; Seliger et al, 1997). Three different types of
antigen processing and/or presentation defects in tumour cells
have been documented (reviewed by Khanna, 1998). Firstly, loss
of surface MHC class I expression, caused by structural alterations
or dysregulation of the MHC class I molecules, probably repre-
sents one of the most important strategies used by tumour cells to
evade CTL-mediated recognition. A second immune escape
mechanism involves abnormalities in processing of endogenous
antigens. For example, a down-regulated expression of LMP2 and
LMP7, two subunits of the multicatalytic proteasome complex,
blocks the generation of peptide epitopes. Finally, complete dele-
tion of coding sequences or point mutations in peptide transporter
genes resulting in loss of TAP-1 and TAP-2 expression inhibits the
transport of peptide epitopes from the cytoplasmic compartment
into the endoplasmic reticulum. Tumour cells can exhibit either
one or a combination of these defects to avoid recognition by
CTLs. Since all these immune escape mechanisms will impair the
effectiveness of CTL-based immunotherapy approaches, it is
highly desirable to establish the antigen-presenting capacities of a
given tumour before setting out to develop such a therapy.
Immunohistology and fluorescence-activated cell sorting
(FACS) analysis, two assays based on antibody binding, have been
widely used to analyse the presence of MHC class I molecules on
tumour cells (Garrido et al, 1993; Marincola et al, 1994b).
However, drawbacks of these assays are the restricted sensitivity
and the fact that only expression of MHC class I molecules is
measured rather than the capacity of the tumour cells to process
and present endogenous antigens. Specific lysis by high-affinity
CTLs can be induced by only a small number (< 10–100) of
ligands per target (Demotz et al, 1990; Harding and Unanue, 1990;
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Christinck et al, 1991; Sykulev et al, 1996). Consequently, a poor
or negligible expression of MHC class I molecules as determined
by immunohistology or FACS analysis, does not necessarily indi-
cate complete absence of recognition by CTLs.
The present study describes a method to directly determine the
antigen-presenting properties of (tumour) cells using influenza
virus as a tool. In this approach, tumour cells which, after virus
infection, process and present viral antigens properly, will be
recognized and lysed by influenza-specific CTLs while absence of
lysis indicates the presence of defects in the antigen-processing
machinery. To evaluate the potential of this influenza virus-based
method we used the murine neuroblastoma (NB) C1300, a well-
established model for human disease (Ziegler et al, 1997). NBs are
poorly immunogenic and characterized by low expression of MHC
class I antigens (Lampson et al, 1983). Nevertheless, we observed
that influenza-infected NB41A3 cells are efficiently lysed by
influenza-specific CTLs. This result indicates that early steps in
antigen processing are not impaired in NB41A3 cells, that a small
number of antigen-MHC class I complexes is sufficient to allow
recognition by specific CTLs, and that NB tumour cells are vulner-
able to CTL-mediated cytotoxicity.
MATERIALS AND METHODS
Cell lines
The murine C1300 neuroblastoma cell line, clone NB41A3,
originating from an A/J mouse (H-2DdKk), the L929 fibroblasts
(H-2Kk), and the mastocytoma cell line P815 (H-2Dd) were
obtained from the American Type Culture Collection (ATCC,
Rockville, MD, USA). Cells were cultured in RPMI-1640 medium
(Gibco-BRL, Breda, The Netherlands) supplemented with 10%
heat-inactivated fetal calf serum (FCS; PAA Laboratories GmbH,
Austria) and 1 mM glutamine.
Antibodies
Monoclonal antibody (mAb) reactive with mouse MHC class I H-
2Kk (mouse IgG2a) was purchased from ATCC (HB-16 16-1-11N
hybridoma cell line). mAb to MHC class I H-2Dd (mouse IgG2a,
MCA 1055) was obtained from Serotec (Apeldoorn, The
Netherlands). Fluorescein isothiocyanate (FITC)-conjugated goat
anti-(mouse IgG) was purchased from Nordic Immunological
Laboratories (Tilburg, The Netherlands).
Treatment of cells with interferon a
NB41A3 cells were cultured in fresh medium containing 750 U
ml–1 murine recombinant interferon g (IFN-g; Gibco-BRL). The
cells were incubated for 3 days and washed in medium before use.
Immunofluorescence
IFN-g-stimulated or non-stimulated NB41A3 cells (5 ´ 105) were
washed twice in cold phosphate-buffered saline (PBS) containing
1% bovine serum albumin (BSA; Sigma, Zwijndrecht, The
Netherlands) and incubated with monoclonal anti-H-2Dd or anti-
H-2Kk antibodies in pre-tested concentrations for 30 min at 0°C.
P815 and L929 cells were used as positive H-2Dd and H-2Kk
controls respectively. Cells were then washed three times and were
further incubated for 30 min at 0°C with FITC-conjugated goat
anti-(mouse IgG) antibodies. After washing, the cells were resus-
pended in the same medium plus propidium iodide to exclude dead
cells during analysis. Stained cells were analysed on an Epics-
Elite flow cytometer (Coulter-Electronics, Hialeah, FL, USA).
The percentage of positive cells was determined by comparison of
the fluorescence labelling to control cells labelled with secondary
antibody alone.
Induction of CTLs
Six- to 8-week-old female A/J mice (H-2DdKk) were obtained
from Harlan (Zeist, The Netherlands) and maintained in our
animal facilities. For sensitization in vivo, mice were given
intraperitoneal (i.p.) injections of 0.1 ml allantoic fluid containing
influenza A/Port Chalmers/1/73 (H3N2) (107 infectious units ml–1)
kindly provided by Solvay Pharmaceuticals (Weesp, The
Netherlands). Two weeks later, splenocytes from the immunized
mice were re-stimulated in vitro for 5 days with influenza-infected
syngeneic spleen cells or with influenza-infected NB41A3 cells
at an effector:stimulator ratio of 5:1. Spleen cells were collected
and assayed for cytotoxic activity against influenza virus in a 4-h
51Cr-release assay.
Cytotoxicity assays
One million influenza-infected and non-infected NB41A3 cells
were labelled with 20mCi Na2
51CrO4 (Amersham, UK) for 1 h.
These labelled target cells (104 in 0.05 ml medium per well) were
then cocultured with serial dilutions of effector cells (0.1 ml per
well) in round-bottomed microtiter wells. After 4 h incubation at
37°C, 0.1 ml supernatant was collected for g-radiation counting.
Medium with or without 0.5% Triton X-100 (Sigma) was used for
the determination of maximal release or spontaneous release
respectively. The percentage specific lysis was calculated as
[(experimental release – spontaneous release)/(maximal release –
spontaneous release)]´ 100%. Where indicated, cytolytic activity
was blocked by including saturating concentrations of anti-MHC I
Dd or anti-MHC I Kk during labelling of target cells with Na2
51CrO4.
Mean radioactivity was determined from triplicate cultures.
RESULTS
Expression of MHC class I molecules Dd and Kk on
NB41A3 cells
FACScan analyses were performed to evaluate the expression of
MHC class I molecules Dd and Kk on NB41A3. Under physio-
logical conditions in the absence of IFN-g, MHC class I Dd and Kk
Table 1 Flow cytometric analysis of the expression of MHC class I
molecules Dd and Kk
Cell line Mean fluorescence
MHC I Dd MHC I Kk
P815 183.7 ND
L929 ND 63.9
NB41A3 24.1 38.5
IFN-g-stimulated NB41A3 86.5 99.7
Infected NB41A3 (2.5 h) 21.3 36.8
Infected NB41A3 (6 h) 25.1 45.4
ND, not determined.1476 DCJ Spierings et al
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molecules were expressed to low and moderate extents
respectively, as compared to their expression on P815 (H-2Dd) or
L929 (H-2Kk) cells (Table 1). Treatment with IFN-g (750 U ml–1)
for 3 days induced an up-regulation of the expression of both Dd
and Kk.
Influenza virus infection is known to induce IFN-a and IFN-b
which in turn can induce up-regulation of MHC class I molecules
(Halloran et al, 1989). We therefore evaluated the effect of acute
influenza virus infection on expression of MHC class I molecules
by staining NB41A3 cells 2.5 or 6 h post-infection. As shown in
Figure 1, influenza virus infection of NB41A3 cells did not affect
the expression of either MHC class I molecule on NB41A3 cells.
MHC class I-restricted lysis of infected NB41A3 cells by
influenza-specific CTLs
To investigate the antigen-presenting capacities, NB41A3 cells
were infected with influenza virus A/Port Chalmers/1/73 (H3N2)
and their susceptibility to killing by influenza-specific CTLs was
determined. Influenza-specific CTLs were generated in A/J mice
by i.p. immunization with 106 infectious units of Port Chalmers
virus. As demonstrated in Figure 2A, virus-infected NB41A3
cells were efficiently lysed by influenza-specific CTLs (58%
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Figure 1 Expression of MHC class I molecules on NB41A3 cells. NB41A3
cells were either untreated (A and E), treated with 750 U ml–1 IFN-g for 3
days (B and F), or infected with influenza virus for 2.5 h (C and G) or 6 h
(D and H) and then incubated with monoclonal antibodies to MHC class I Dd
(A–D) or MHC class I Kk (E–H). Cells were stained with a secondary FITC-
conjugated rabbit anti-(mouse IgG) antibody and then analysed on the
fluorescence-activated cell sorter. Fluorescence intensity was plotted vs. the
cell number. Control cells (curves on the left in each panel) were stained with
the secondary antibody only
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Figure 2 Susceptibility of influenza-infected NB41A3 cells to influenza-
specific CTLs. Influenza-specific CTLs were prepared by in vivo
immunization of A/J mice with allantois fluid containing influenza virus Port
Chalmers followed by in vitro restimulation with influenza-infected
splenocytes as described in Material and Methods. Cytotoxic responses
were measured at different effector-to-target ratios in a 4-h 51Cr-release
assay. Susceptibility of non-stimulated NB41A3 cells (A) was compared with
that of IFN-g-stimulated NB41A3 cells (B). s, NB41A3 cells; n, influenza-
infected NB41A3 cellsspecific lysis at E:T ratio 30:1). The sensitivity to lysis was
increased to 78% when NB41A3 cells were stimulated with IFN-g
for 3 days prior to the 51Cr-release assay (Figure 2B).
To identify possible H-2 restriction elements, the ability of
appropriate antibodies to inhibit lysis of influenza-infected
NB41A3 cells by influenza-specific CTLs was determined. As
demonstrated in Figure 3, lysis of infected NB41A3 cells was
partially inhibited by antibodies against MHC I Dd, but not by anti-
bodies against Kk (48% and 0% inhibition respectively).
In vitro stimulation of influenza-primed CTLs by
infected NB41A3 cells
In order to test the ability of NB41A3 cells to stimulate spleen
cells in vitro, bulk T cells of mice primed with Port Chalmers virus
were incubated with virus-infected NB41A3 cells for 5 days.
Cytotoxic activity of these T cells against infected targets was
compared to that of T cells stimulated by influenza-infected spleen
cells. As shown in Figure 4, infected NB41A3 cells could effi-
ciently stimulate influenza-primed CTLs in vitro. Both splenocyte-
and NB41A3-stimulated CTLs showed a similar level of specific
lysis of influenza-infected target cells. Interestingly, lysis of non-
infected targets being rather high for splenocyte-stimulated CTLs
in this experiment (Figure 4A), was considerably lower when
restimulation was performed with infected NB41A3 cells (Figure
4B).
DISCUSSION
In the present study, we used influenza virus as a tool to determine
the antigen presenting capacities of NB tumour cells. Clearly,
influenza-infected NB41A3 cells can be recognized and lysed in
vitro by influenza-specific CTLs only if the cells process and
present viral antigens properly. Thus, the influenza assay measures
three important steps in the MHC class I processing pathway,
e.g. (i) processing of influenza-derived proteins to presentable
peptides; (ii) transport of these peptides from the cell cytosol to the
ER by TAP-1/TAP-2; (iii) presentation of the peptides in context
of MHC class I molecules on the cell surface. Therefore, this func-
tional assay evaluates not only the level of cell surface expression
of MHC class I molecules, but also defects in the function of the
proteasome subunits LMP2/LMP7 and the peptide-transporters
TAP-1/TAP-2.
In addition, the influenza virus-based assay also measures the
susceptibility of tumour cells for lysis by CTLs. T cells can cause
the destruction of target cells by two mechanisms, one involving
the death-signalling receptor CD95 (also called APO-1 or Fas) and
the other involving the perforin-granzyme system. Both mecha-
nisms eventually activate the caspase cascade leading to apoptosis
(Froelich et al, 1996; Nagata, 1997). According to Strand and
Galle (1998), an impaired anti-tumour immune response can be
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Figure 3 Inhibition of CTL-mediated lysis of infected NB41A3 target cells by
antibodies to MHC class I molecules. Influenza-specific CTLs were prepared
as described before. Cytotoxic activity at a 30:1 effector-to-target ratio was
determined in a 4-h 51Cr-release assay following an incubation of the target
cells with saturating amounts of antibodies (60 min at 37°C). Antibodies used
were anti-MHC I Dd or anti-MHC I Kk
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Figure 4 Evaluation of the CTL-stimulating capacities of influenza-infected
NB41A3 cells. Influenza-primed CTLs were restimulated in vitro with
influenza-infected splenocytes (A) or influenza-infected NB41A3 cells (B).
Cytotoxic responses were measured at different effector-to-target ratios in a
4-h 51Cr-release assay. (s) NB41A3 cells; (n) influenza-infected NB41A3
cells
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caused by reduced tumour-cell responsiveness to stimulation of
CD95. In fact, many cancer cells are relatively resistant to CD95-
mediated apoptosis because of loss of CD95 (no triggering of T-
cell-induced apoptosis) or defects in the CD95 signalling pathway
(no response to T-cell-induced apoptosis). Furthermore, many
tumour cells overexpress apoptosis inhibitors such as Bcl-2 and
Bcl-2 family members, which abrogate not only CD95-induced
but also perforin-mediated apoptosis. The presented influenza
virus-based assay can be used to evaluate the presence of such
apoptosis-inhibiting mechanisms and can help to demonstrate
susceptibility of tumour cells to CTL-mediated lysis in general.
To test the influenza virus-based method we used the murine
neuroblastoma (NB) C1300, a well-established model for human
disease (Ziegler et al, 1997). NB is a typical poorly immunogenic
tumour and incapable to elicit a specific immune response by
virtue of a low MHC class I expression and its deficiency in MHC
class II, costimulatory and adhesion molecules (Lampson et al,
1983; Main et al, 1985; Zier et al, 1990; Katsanis et al, 1995). The
low expression of MHC class I molecules was confirmed in this
study. MHC class I down-regulation in NB cells is probably
caused by overexpression of the N-myc oncogene which lowers
the expression of the p50 subunit of NF-kB, a transcription factor
binding to the enhancer-A element in the MHC class I gene
promoter (Bernards et al, 1986; Lenardo et al, 1989; van’t Veer et
al, 1993).
In the context of the antigen-presentation assay, influenza-
infected NB cells were efficiently recognized and lysed by
influenza-specific CTLs despite the low expression of the relevant
MHC class I molecules. Lysis was not due to MHC class I up-
regulation by virus infection since infected NB cells showed no
differences in expression of these molecules in comparison with
non-infected NB cells. Although an up-regulated expression of
MHC class I molecules by IFN-g stimulation slightly increased the
sensitivity of NB tumour cells to lysis, the limited number of
MHC class I molecules expressed under physiological conditions
appeared to be sufficient for efficient recognition by CTLs.
CTL-mediated killing of influenza-infected NB cells appeared
to be restricted by H-2Dd as shown by the fact that antibodies to
H-2Dd but not antibodies to H-2Kk could reduce lysis.
Interestingly, although viral nucleoproteins (NP) are often immun-
odominant targets for CTLs (Townsend et al, 1984; Yewdell et al,
1985), a conserved H-2Kk-binding epitope (AA50–57: SDYE-
GRLI), derived from influenza NP (Parker and Gould, 1996) does
obviously not play an important role in the killing of infected NB
cells. Limited importance of an immunodominant NP-derived
epitope was found earlier for peptide TYQRTALV (AA147–155)
of influenza A/Puerto Rico/8/34 (H1N1). CTLs restimulated with
influenza-infected cells, thus with a number of epitopes simultane-
ously, failed to recognize target cells which had been loaded with
this NP peptide only (own observations). With respect to lysis of
the NB cells, unknown H-2Dd-specific epitopes derived from NP,
the matrix protein (M), or, perhaps, haemagglutinin (HA) were
apparently immunodominant since lysis was restricted by H-2Dd.
Unfortunately, influenza virus strain A/Port Chalmers/1/73
(H3N2) is poorly characterized as far as H-2-binding epitopes are
concerned.
Besides being targets for influenza-specific CTLs, infected NB
cells were also capable of stimulating bulk spleen cells in vitro.
Stimulated spleen cells from influenza-primed mice, but not from
PBS-injected control mice, could efficiently lyse influenza-
infected target cells. It might be argued that stimulation was not
mediated by the primarily infected NB41A3 cells but by secon-
darily infected spleen cells. Indeed, infected NB cells used as
stimulators will produce virus. However, due to lack of a proper
trypsin-like protease, cleavage of the viral haemagglutinin does
not take place rendering the produced virus uninfectious (Klenk
et al, 1975; Lazarowicz and Choppin, 1975). Therefore, stimula-
tion of T cells by cells other than the initially infected NB cells can
be excluded.
In summary, the present study demonstrates that the poorly
immunogenic NB cells: (i) do possess a functional antigen-
processing machinery, (ii) present antigen despite a low surface
expression of the relevant MHC class I molecules, and (iii) are
susceptible to lysis by activated CTLs. The efficient lysis of NB
cells in this assay implies that NBs are suitable targets for
immunotherapy if an effective way of immunization can be found
to activate NB-specific CTLs. This paper presents a reliable and
widely applicable functional assay using the influenza virus as a
tool to determine the antigen processing and presenting capacities
of tumour cells and to test their susceptibility to lysis by activated
CTLs.
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